MalcolmBrennerMD

Pediatric Hematology & Oncology • Houston, TX

Professor of Medicine, Baylor College of Medicine

Join to view full profile

Dr. Brenner is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Brenner's full profile

Already have an account?

Office
6565 Fannin St

Houston, TX 77030
Phone+1 713-441-1450

Fax+1 713-793-1232

Education & Training

University of Cambridge School of MedicineClass of 1981

Certifications & Licensure

TX State Medical License 2002 - 2025
TN State Medical License 1992 - 2001

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
Top Doctors:SE Texas Castle Connolly, 2013
America's Top Doctors for Cancer Castle Connolly, 2005-2013

Clinical Trials

Bone Marrow Transplant From Donor Using Less Toxic Conditioning for Patient With High Risk Hemoglobinopathies Start of enrollment: 2000 Aug 01
Terminated
Phase 2
Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies Start of enrollment: 2000 Aug 01
Terminated
Phase 2
High Dose Chemo/Radiotherapy and Hematopoietic Stem Cell Transplant for Patients With Multiple Sclerosis Start of enrollment: 1999 Apr 01
Completed
Phase 2
Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases Start of enrollment: 2002 Nov 01
Completed
Phase 1, Phase 2
Monoclonal Antibody Conditioning for Allogeneic Stem Cell Transplantation of Patients With Inherited Metabolic Storage Diseases Start of enrollment: 2002 Jun 01
Terminated
Phase 1, Phase 2
Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell Transplantation Start of enrollment: 2003 Feb 01
Completed
Phase 1
Treatment of Chronic Lymphocytic B-Leukemia With IL-2 and CD-40 Autologous Tumor Cells Start of enrollment: 2002 Dec 01
Completed
Phase 1
Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor Vaccine Start of enrollment: 1999 Jun 01
Completed
Phase 1
Using Gene Modified Neuroblastoma Cells for the Treatment of Relapsed/Refractory Neuroblastoma Start of enrollment: 1997 Nov 01
Completed
Phase 1
Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells Start of enrollment: 2003 Jan 01
Completed
Phase 1
Lymphocytic B-Leukemia (B-CLL) w/Human IL-2 Gene Modified & Human CD40 Ligand-Expressing Autologous Tumor Cells Start of enrollment: 2005 Sep 01
Withdrawn
Phase 1
Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's Lymphoma Start of enrollment: 2006 Sep 01
Terminated
Phase 1
Treatment of B-Chronic Lymphocytic Leukemia (B-CLL) With Autologous CD40 Ligand and IL-2-Expressing Tumor Cells Start of enrollment: 2006 Dec 01
Completed
Phase 1
Use of Rft5-Dga to Deplete Alloreactive Cells for Pts With Fanconi Anemia After Haploidentical SCT Start of enrollment: 2002 Mar 01
Terminated
Phase 1
Evaluating the Use of RFT5-dgA to Deplete Alloreactive Cells Prior to Haploidentical Stem Cell Transplantation Start of enrollment: 2000 Jul 01
Completed
Phase 1
CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene Start of enrollment: 2008 Dec 01
Active, not recruiting
Phase 1
Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells Start of enrollment: 2021 Aug 02
Recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers.
David Steffin, Nisha Ghatwai, Antonino Montalbano, Purva Rathi, Amy N Courtney
Nature. 2024-11-27
8 citations
Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors.
Frank Y Lin, Austin Stuckert, Candise Tat, Mark White, Lucia Ruggieri
Journal of Clinical Oncology. 2024-08-10
2 citations
Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity.
Royce Ma, Mae Woods, Phillip Burkhardt, Noah Crooks, Dayenne G van Leeuwen
Cell Reports. Medicine. 2024-07-16

Journal Articles

EBV/LMP-specific T Cells Maintain Remissions of T and B Cell EBV Lymphomas After Allogeneic Bone Marrow Transplantation
Stephen Gottschalk, Rayne Rouce, Catherine M Bollard, Malcolm K Brenner, Helen E Heslop, Blood
Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies
Jordan S Orange, Malcolm K Brenner, Clinical Cancer Research
Onward and Upward for Immuno-Oncology
Malcolm Brenner, MD, Annals of Palliative Medicine

Abstracts/Posters

Enhancing the Effect of CLL-1 CAR T Cells with Interleukin-15 for Treatment of Acute Myeloid Leukemia
Malcolm K. Brenner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed/Refractory T-Cell MalignanciesClinically Relevant Abstract
Malcolm K. Brenner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Single Cell RNA Sequencing Identifies Transcriptional Programs That Enhance Anti-Tumor Function of Transgenic CD4+ T Cells Redirected with TCR and CD8__
Malcolm K. Brenner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Targeting Lymphomas Using Non-Engineered, Multi-Antigen Specific T Cells
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Tessa Therapeutics, Baylor College of Medicine Execute Agreement for Global Commercial Rights to ‘Off-the-Shelf’ CAR-T PlatformNovember 7th, 2022
Cell Therapy Pioneer: Modality Could Be Solution to ‘Pretty Large Cadre’ of DiseasesOctober 17th, 2022
Triumvira Immunologics Establishes Scientific Advisory BoardJanuary 18th, 2022
Join now to see all